Frequency Therapeutics — Hearing Loss Regeneration

#1,562
Some how Im thinking there is a confidential clause for those involved....reality is if this works an the beans get spilt too soon people will bombard them for it, fda wont let them use it freely an they would not be able to manufacture enough. This would result in utter chaos. If this works I doubt they will say anything with out a year supply at minimum on the shelf.
 
#1,563
Contrast said:
may this is not confirmed

do not say this will cause tinnitus to worsen, they just have to put this crap just incase something goes wrong
Click to expand...
This happens in every intratympanic injection procedure, there is a temporary "damage" to the tympanic membrane which causes our constant and beloved tinnitus which fades away, they just have to mention it
 
#1,564
Onebigburb said:
Some how Im thinking there is a confidential clause for those involved....reality is if this works an the beans get spilt too soon people will bombard them for it, fda wont let them use it freely an they would not be able to manufacture enough. This would result in utter chaos. If this works I doubt they will say anything with out a year supply at minimum on the shelf.
Click to expand...

That reminds me of when the people found out Jesus was healing people they mobbed the house he was in and they tore off the roof to lower a crippled person down in there.
 
#1,565
Iliasp said:
This happens in every intratympanic injection procedure, there is a temporary "damage" to the tympanic membrane which causes our constant and beloved tinnitus which fades away, they just have to mention it
Click to expand...
Right but they also mention the hole can stay forever and never heal itself.

Do we have any info about this kind of injection? Can it be dangerous for the eardrum? I understand they're actually going through on purpose. I didn't know a hole in the eardrum could be repaired by the body on its own.
 
#1,566
Official patent for one of FTX's many approaches to their therapeutic intervention with FX-322. I copied and pasted the link to the full disclosure, and I copied below some of the more interesting excerpts, especially the excerpt where they elude to how their methodology of expanding and differentiating supporting cells can yield new cochlear cells that are organized and placed in the necessary rosette pattern integral for proper hearing function. Source:


https://patents.google.com/patent/US9968615B2/en



Among other things, the methods presented here are useful for the preparation of pharmaceutical formulations for the prophylaxis and/or treatment of acute and chronic ear disease and hearing loss, dizziness and balance problems especially of sudden hearing loss, acoustic trauma, hearing loss due to chronic noise exposure, presbycusis, trauma during implantation of the inner ear prosthesis (insertion trauma), dizziness due to diseases of the inner ear area, dizziness related and/or as a symptom of Meniere's disease, vertigo related and/or as a symptom of Meniere's disease, tinnitus, and hearing loss due to antibiotics and cytostatics and other drugs.

When cochlea supporting cell populations are treated with the compound, whether the population is in vivo or in vitro, the treated supporting cells exhibit stem-like behavior in that the treated supporting cells have the capacity to proliferate and differentiate and, more specifically, differentiate into cochlear hair cells. Preferably, the compound induces and maintains the supporting cells to produce daughter stem cells that can divide for many generations and maintain the ability to have a high proportion of the resulting cells differentiate into hair cells. In certain embodiments, the proliferating stem cells express stem cell markers which may include Lgr5, Sox2, Opem1, Phex, lin28, Lgr6, cyclin D1,Msx1, Myb, Kit, Gdnf3, Zic3, Dppa3, Dppa4, Dppa5, Nanog, Esrrb, Rex1, Dnmt3a, Dnmt3b, Dnmt31, Utf1, Tcl1, Oct4, Klf4, Pax6, Six2, Zic1, Zic2, Otx2, Bmi1, CDX2, STAT3, Smad1, Smad2, smad2/3, smad4, smad5, and/or smad7.

In some embodiments, the method of the present disclosure may be used to maintain, or even transiently increase sternness (i.e., self-renewal) of a pre-existing supporting cell population prior to significant hair cell formation. In some embodiments, the pre-existing supporting cell population comprises inner pillar cells, outer pillar cells, inner phalangeal cells, Deiter cells, Hensen cells, Boettcher cells, and/or Claudius cells. Morphological analyses with immunostaining (including cell counts) and lineage tracing across a Representative Microscopy Samples may be used to confirm expansion of one or more of these cell-types. In some embodiments, the pre-existing supporting cells comprise Lgr5+ cells. Morphological analyses with immunostaining (including cell counts) and qPCR and RNA hybridization may be used to confirm Lgr5 upregulation amongst the cell population.

Advantageously, the methods of the present disclosure achieve these goals without the use of genetic manipulation. Germ-line manipulation used in many academic studies is not a therapeutically desirable approach to treating hearing loss. In general, the therapy preferably involves the administration of a small molecule, peptide, antibody, or other non-nucleic acid molecule or nucleic acid delivery vector unaccompanied by gene therapy. In certain embodiments, the therapy involves the administration of a small organic molecule. Preferably, hearing protection or restoration is achieved through the use of a (non-genetic) therapeutic that is injected in the middle ear and diffuses into the cochlea.

The cochlea relies heavily on all present cell types, and the organization of these cells is important to their function. As supporting cells play an important role in neurotransmitter cycling and cochlear mechanics. Thus, maintaining a rosette patterning within the organ of Corti may be important for function. Cochlear mechanics of the basilar membrane activate hair cell transduction. Due to the high sensitivity of cochlear mechanics, it is also desirable to avoid masses of cells. In all, maintaining proper distribution and relation of hair cells and supporting cells along the basilar membrane, even after proliferation, is likely a desired feature for hearing as supporting cell function and proper mechanics is necessary for normal hearing.

In one embodiment of the present disclosure, the cell density of hair cells in a cochlear cell population is expanded in a manner that maintains, or even establishes, the rosette pattern characteristic of cochlear epithelia.

In accordance with one aspect of the present disclosure, the cell density of hair cells may be increased in a population of cochlear cells comprising both hair cells and supporting cells. The cochlear cell population may be an in vivo population (i.e., comprised by the cochlear epithelium of a subject) or the cochlear cell population may be an in vitro (ex vivo) population. If the population is an in vitro population, the increase in cell density may be determined by reference to a Representative Microscopy Sample of the population taken prior and subsequent to any treatment. If the population is an in vivo population, the increase in cell density may be determined indirectly by determining an effect upon the hearing of the subject with an increase in hair cell density correlating to an improvement in hearing.

In one embodiment, supporting cells placed in a Stem Cell Proliferation Assay in the absence of neuronal cells form ribbon synapses.

In a native cochlea, patterning of hair cells and supporting cells occurs in a manner parallel to the basilar membrane. In one embodiment of the present disclosure, the proliferation of supporting cells in a cochlear cell population is expanded in a manner that the basilar membrane characteristic of cochlear epithelia.

In certain embodiments, the stem cell population is of an in vivo subject, and the method is a treatment for hearing loss and/or vestibular dysfunction (e.g., wherein the generation of inner ear hair cells from the expanded population of stem cells results in partial or full recovery of hearing loss and/or improved vestibular function).
 
#1,567
Enclave said:
Official patent for one of FTX's many approaches to their therapeutic intervention with FX-322. I copied and pasted the link to the full disclosure, and I copied below some of the more interesting excerpts, especially the excerpt where they elude to how their methodology of expanding and differentiating supporting cells can yield new cochlear cells that are organized and placed in the necessary rosette pattern integral for proper hearing function. Source:


https://patents.google.com/patent/US9968615B2/en



Among other things, the methods presented here are useful for the preparation of pharmaceutical formulations for the prophylaxis and/or treatment of acute and chronic ear disease and hearing loss, dizziness and balance problems especially of sudden hearing loss, acoustic trauma, hearing loss due to chronic noise exposure, presbycusis, trauma during implantation of the inner ear prosthesis (insertion trauma), dizziness due to diseases of the inner ear area, dizziness related and/or as a symptom of Meniere's disease, vertigo related and/or as a symptom of Meniere's disease, tinnitus, and hearing loss due to antibiotics and cytostatics and other drugs.

When cochlea supporting cell populations are treated with the compound, whether the population is in vivo or in vitro, the treated supporting cells exhibit stem-like behavior in that the treated supporting cells have the capacity to proliferate and differentiate and, more specifically, differentiate into cochlear hair cells. Preferably, the compound induces and maintains the supporting cells to produce daughter stem cells that can divide for many generations and maintain the ability to have a high proportion of the resulting cells differentiate into hair cells. In certain embodiments, the proliferating stem cells express stem cell markers which may include Lgr5, Sox2, Opem1, Phex, lin28, Lgr6, cyclin D1,Msx1, Myb, Kit, Gdnf3, Zic3, Dppa3, Dppa4, Dppa5, Nanog, Esrrb, Rex1, Dnmt3a, Dnmt3b, Dnmt31, Utf1, Tcl1, Oct4, Klf4, Pax6, Six2, Zic1, Zic2, Otx2, Bmi1, CDX2, STAT3, Smad1, Smad2, smad2/3, smad4, smad5, and/or smad7.

In some embodiments, the method of the present disclosure may be used to maintain, or even transiently increase sternness (i.e., self-renewal) of a pre-existing supporting cell population prior to significant hair cell formation. In some embodiments, the pre-existing supporting cell population comprises inner pillar cells, outer pillar cells, inner phalangeal cells, Deiter cells, Hensen cells, Boettcher cells, and/or Claudius cells. Morphological analyses with immunostaining (including cell counts) and lineage tracing across a Representative Microscopy Samples may be used to confirm expansion of one or more of these cell-types. In some embodiments, the pre-existing supporting cells comprise Lgr5+ cells. Morphological analyses with immunostaining (including cell counts) and qPCR and RNA hybridization may be used to confirm Lgr5 upregulation amongst the cell population.

Advantageously, the methods of the present disclosure achieve these goals without the use of genetic manipulation. Germ-line manipulation used in many academic studies is not a therapeutically desirable approach to treating hearing loss. In general, the therapy preferably involves the administration of a small molecule, peptide, antibody, or other non-nucleic acid molecule or nucleic acid delivery vector unaccompanied by gene therapy. In certain embodiments, the therapy involves the administration of a small organic molecule. Preferably, hearing protection or restoration is achieved through the use of a (non-genetic) therapeutic that is injected in the middle ear and diffuses into the cochlea.

The cochlea relies heavily on all present cell types, and the organization of these cells is important to their function. As supporting cells play an important role in neurotransmitter cycling and cochlear mechanics. Thus, maintaining a rosette patterning within the organ of Corti may be important for function. Cochlear mechanics of the basilar membrane activate hair cell transduction. Due to the high sensitivity of cochlear mechanics, it is also desirable to avoid masses of cells. In all, maintaining proper distribution and relation of hair cells and supporting cells along the basilar membrane, even after proliferation, is likely a desired feature for hearing as supporting cell function and proper mechanics is necessary for normal hearing.

In one embodiment of the present disclosure, the cell density of hair cells in a cochlear cell population is expanded in a manner that maintains, or even establishes, the rosette pattern characteristic of cochlear epithelia.

In accordance with one aspect of the present disclosure, the cell density of hair cells may be increased in a population of cochlear cells comprising both hair cells and supporting cells. The cochlear cell population may be an in vivo population (i.e., comprised by the cochlear epithelium of a subject) or the cochlear cell population may be an in vitro (ex vivo) population. If the population is an in vitro population, the increase in cell density may be determined by reference to a Representative Microscopy Sample of the population taken prior and subsequent to any treatment. If the population is an in vivo population, the increase in cell density may be determined indirectly by determining an effect upon the hearing of the subject with an increase in hair cell density correlating to an improvement in hearing.

In one embodiment, supporting cells placed in a Stem Cell Proliferation Assay in the absence of neuronal cells form ribbon synapses.

In a native cochlea, patterning of hair cells and supporting cells occurs in a manner parallel to the basilar membrane. In one embodiment of the present disclosure, the proliferation of supporting cells in a cochlear cell population is expanded in a manner that the basilar membrane characteristic of cochlear epithelia.

In certain embodiments, the stem cell population is of an in vivo subject, and the method is a treatment for hearing loss and/or vestibular dysfunction (e.g., wherein the generation of inner ear hair cells from the expanded population of stem cells results in partial or full recovery of hearing loss and/or improved vestibular function).
Click to expand...
So from reading all that, they're saying FX-322 can cure not only tinnitus but other ear disorders as well?
 
#1,568
Enclave said:
Official patent for one of FTX's many approaches to their therapeutic intervention with FX-322. I copied and pasted the link to the full disclosure, and I copied below some of the more interesting excerpts, especially the excerpt where they elude to how their methodology of expanding and differentiating supporting cells can yield new cochlear cells that are organized and placed in the necessary rosette pattern integral for proper hearing function. Source:


https://patents.google.com/patent/US9968615B2/en



Among other things, the methods presented here are useful for the preparation of pharmaceutical formulations for the prophylaxis and/or treatment of acute and chronic ear disease and hearing loss, dizziness and balance problems especially of sudden hearing loss, acoustic trauma, hearing loss due to chronic noise exposure, presbycusis, trauma during implantation of the inner ear prosthesis (insertion trauma), dizziness due to diseases of the inner ear area, dizziness related and/or as a symptom of Meniere's disease, vertigo related and/or as a symptom of Meniere's disease, tinnitus, and hearing loss due to antibiotics and cytostatics and other drugs.

When cochlea supporting cell populations are treated with the compound, whether the population is in vivo or in vitro, the treated supporting cells exhibit stem-like behavior in that the treated supporting cells have the capacity to proliferate and differentiate and, more specifically, differentiate into cochlear hair cells. Preferably, the compound induces and maintains the supporting cells to produce daughter stem cells that can divide for many generations and maintain the ability to have a high proportion of the resulting cells differentiate into hair cells. In certain embodiments, the proliferating stem cells express stem cell markers which may include Lgr5, Sox2, Opem1, Phex, lin28, Lgr6, cyclin D1,Msx1, Myb, Kit, Gdnf3, Zic3, Dppa3, Dppa4, Dppa5, Nanog, Esrrb, Rex1, Dnmt3a, Dnmt3b, Dnmt31, Utf1, Tcl1, Oct4, Klf4, Pax6, Six2, Zic1, Zic2, Otx2, Bmi1, CDX2, STAT3, Smad1, Smad2, smad2/3, smad4, smad5, and/or smad7.

In some embodiments, the method of the present disclosure may be used to maintain, or even transiently increase sternness (i.e., self-renewal) of a pre-existing supporting cell population prior to significant hair cell formation. In some embodiments, the pre-existing supporting cell population comprises inner pillar cells, outer pillar cells, inner phalangeal cells, Deiter cells, Hensen cells, Boettcher cells, and/or Claudius cells. Morphological analyses with immunostaining (including cell counts) and lineage tracing across a Representative Microscopy Samples may be used to confirm expansion of one or more of these cell-types. In some embodiments, the pre-existing supporting cells comprise Lgr5+ cells. Morphological analyses with immunostaining (including cell counts) and qPCR and RNA hybridization may be used to confirm Lgr5 upregulation amongst the cell population.

Advantageously, the methods of the present disclosure achieve these goals without the use of genetic manipulation. Germ-line manipulation used in many academic studies is not a therapeutically desirable approach to treating hearing loss. In general, the therapy preferably involves the administration of a small molecule, peptide, antibody, or other non-nucleic acid molecule or nucleic acid delivery vector unaccompanied by gene therapy. In certain embodiments, the therapy involves the administration of a small organic molecule. Preferably, hearing protection or restoration is achieved through the use of a (non-genetic) therapeutic that is injected in the middle ear and diffuses into the cochlea.

The cochlea relies heavily on all present cell types, and the organization of these cells is important to their function. As supporting cells play an important role in neurotransmitter cycling and cochlear mechanics. Thus, maintaining a rosette patterning within the organ of Corti may be important for function. Cochlear mechanics of the basilar membrane activate hair cell transduction. Due to the high sensitivity of cochlear mechanics, it is also desirable to avoid masses of cells. In all, maintaining proper distribution and relation of hair cells and supporting cells along the basilar membrane, even after proliferation, is likely a desired feature for hearing as supporting cell function and proper mechanics is necessary for normal hearing.

In one embodiment of the present disclosure, the cell density of hair cells in a cochlear cell population is expanded in a manner that maintains, or even establishes, the rosette pattern characteristic of cochlear epithelia.

In accordance with one aspect of the present disclosure, the cell density of hair cells may be increased in a population of cochlear cells comprising both hair cells and supporting cells. The cochlear cell population may be an in vivo population (i.e., comprised by the cochlear epithelium of a subject) or the cochlear cell population may be an in vitro (ex vivo) population. If the population is an in vitro population, the increase in cell density may be determined by reference to a Representative Microscopy Sample of the population taken prior and subsequent to any treatment. If the population is an in vivo population, the increase in cell density may be determined indirectly by determining an effect upon the hearing of the subject with an increase in hair cell density correlating to an improvement in hearing.

In one embodiment, supporting cells placed in a Stem Cell Proliferation Assay in the absence of neuronal cells form ribbon synapses.

In a native cochlea, patterning of hair cells and supporting cells occurs in a manner parallel to the basilar membrane. In one embodiment of the present disclosure, the proliferation of supporting cells in a cochlear cell population is expanded in a manner that the basilar membrane characteristic of cochlear epithelia.

In certain embodiments, the stem cell population is of an in vivo subject, and the method is a treatment for hearing loss and/or vestibular dysfunction (e.g., wherein the generation of inner ear hair cells from the expanded population of stem cells results in partial or full recovery of hearing loss and/or improved vestibular function).
Click to expand...
You just won the internet. I am crying. Thank you.
 
Last edited:
#1,571
Ozwel said:
Right but they also mention the hole can stay forever and never heal itself.

Do we have any info about this kind of injection? Can it be dangerous for the eardrum? I understand they're actually going through on purpose. I didn't know a hole in the eardrum could be repaired by the body on its own.
Click to expand...
Itll be fine.
 
#1,573
Pero1234 said:
I think so too...

Have you ever read the safety instructions on childrens toys? Or when riding a rented vehicle? :)

They just want to cover themselves!
Click to expand...
yeah I had glue ear years ago and my doctor was saying they could put tubes in my eardrums to drain the goo, and that they would heal up just fine. I opted out and the glue ear went away on its own.
 
#1,575
JohnAdams said:
if you're worried about the hole in the eardrum there's this.

https://en.wikipedia.org/wiki/Tympanoplasty
Click to expand...

My ENT said that Tympanoplasty = 30dbhl accross all the audiogram.

Actually Tympanoplasty resulting hearing is far from one you could get with a normal eardrum.

But this is what said my ENT, I don't know how good can be tympanoplasty really.
 
#1,576
I asked today my ENT about hearing regeneration :

Me : What do you think about hearing regeneration research, ENT ?

ENT : Well... We are making some advance in hearing regeneration, but it is extremely slow, actually hearing research is progressing like lilliputian steps.
 
#1,578
Felix Dujardin said:
I asked today my ENT about hearing regeneration :

Me : What do you think about hearing regeneration research, ENT ?

ENT : Well... We are making some advance in hearing regeneration, but it is extremely slow, actually hearing research is progressing like lilliputian steps.
Click to expand...
Are you really seeing French ENTs about tinnitus? (lol)

I tried in 2005 (most of them told me it was in my head and it doesn't exist, sent me to the shrink), then 2010 was a bit more about "get used to it" and finally a year ago they gave me a paper to do some yoga + "get used to it". I'm done with them. The best cure I could find in the past 10 years is a girlfriend who is able to understand what it is to live with this.

Trust me: you'll know waaaay before ENTs when a cure is available.
 
#1,579
Felix Dujardin said:
I asked today my ENT about hearing regeneration :

Me : What do you think about hearing regeneration research, ENT ?

ENT : Well... We are making some advance in hearing regeneration, but it is extremely slow, actually hearing research is progressing like lilliputian steps.
Click to expand...
tell them about frequency therapeutics and decibel.
 
#1,582
JohnAdams said:
it's only their jobs. they should be staying up on this knowledge seeing as how thy are the government sanctioned gatekeepers of medicine, and they are making a living off of their niche. effum.
Click to expand...
i dont believe in a conspiracy of wanting to sell hearing aids, but i do believe the hearing aid industry would prefer to completely ignore and play stupid about bio tech trying to treat hearing loss on a biological level.

if someone profits from selling hearing aids, they would not be in favor of their industry being crippled. It's common sense. So far they have done nothing to stop it, just ignore it and tell the public 100 years away for a cure bs.

I am concerned about the future if they actually do get lobbyist in the FDA to stop this.
 
#1,583
Contrast said:
i dont believe in a conspiracy of wanting to sell hearing aids, but i do believe the hearing aid industry would prefer to completely ignore and play stupid about bio tech trying to treat hearing loss on a biological level.

if someone profits from selling hearing aids, they would not be in favor of their industry being crippled. It's common sense. So far they have done nothing to stop it, just ignore it and tell the public 100 years away for a cure bs.

I am concerned about the future if they actually do get lobbyist in the FDA to stop this.
Click to expand...

I dont think that will happen.
 
#1,584
JohnAdams said:
I dont think that will happen.
Click to expand...

If frequency gets bought out by a hearing aid company then we should start worrying. Until then we shouldnt start worrying.

We shouldnt be too hard on ENT's either. They will make their money with the injections of FX-322. I think they are being more realistic than the rest of us for the timetable of all of these cures that are being proposed. Everyone agrees it will happen, and it is just a question of when.
 
#1,585
RB2014 said:
If frequency gets bought out by a hearing aid company then we should start worrying. Until then we shouldnt start worrying.

We shouldnt be too hard on ENT's either. They will make their money with the injections of FX-322. I think they are being more realistic than the rest of us for the timetable of all of these cures that are being proposed. Everyone agrees it will happen, and it is just a question of when.
Click to expand...

Ive been on an emotional downward spiral for 3 months and now that i believe it will happen in the next few years i dont even care and my T has dropped significantly. Weird disease this one.
 
#1,586
It isn't weird, it is perfectly easy to explain: limbic system. Anxiety turns your attention to the danger so you can take actions to protect yourself from it. The more you consider tinnitus as a danger the more your mind/limbic system will focus on it because the rest doesn't matter in term of "danger scale" and the only thing that matters is to fight the intruder. When you consider it not to be a big deal anymore, you can think of other things and let it go...

If you want to know more about Tinnitus and Limbic system:

Tinnitus is not the only "disease" acting like this.
 
#1,587
I applied and was denied via email due to my hearing loss being above 10kz I have mild hearing loss from a rifle shot, with tinnitus. I do association higher frequency loss with mental illness than other tones. We suffer silently but after this cure we will comeback stronger than ever :)
 
#1,589
Can someone point me to the URL of the actual study details? All I'm seeing is a completed one for safety... Thanks!
 

Log in or register to get the full forum benefits!

Register

Register on Tinnitus Talk for free!

Register Now

Similar threads

N
Delix Therapeutics — Neuroplastogen for Hearing Loss
Replies
6
Views
3K
Research News
AverageJoe12
AverageJoe12
N
Hoba Therapeutics' HB-097 for Sensorineural Hearing Loss
Replies
2
Views
1K
Research News
Nick47
N
N
Amber Therapeutics — Brain Implants
Replies
0
Views
776
Research News
Nick47
N
LBE
Intratympanic Lidocaine as a Potent Remedy for Tinnitus in Sudden Sensorineural Hearing Loss
Replies
2
Views
666
Research News
LBE
LBE
I
From Hidden Hearing Loss to Supranormal Auditory Processing by Increasing Neurotrophin 3
Replies
3
Views
2K
Research News
sspencermo
sspencermo
Top Bottom
Back
Forums
Members
Donate
Menu